On March 7, 2025, and again on March 10, scientists, healthcare workers, and more rallied in protest to Trump administration ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

Switching to long-acting ART from oral treatments was cost effective for postpartum women with HIV and improved infant outcomes, researchers said at the Conference on Retroviruses and Opportunistic ...

The lack of available medications in the United States for COVID post-exposure prophylaxis leaves household members in close contact with someone who is infected vulnerable to developing COVID ...

That’s the potential promise of a new study on a drug made by Japanese pharmaceutical company Shionogi. At a scientific ...

Hundreds of HIV doctors and researchers have called on the Trump administration to reverse its sweeping aid funding cuts, saying they are “doing catastrophic harm” to the global fight against AIDS.The ...

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

In 2020, the Conference on Retroviruses and Opportunistic Infections (CROI) was the first scientific conference to move from ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.